| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (NCT03992131) | pharmaand GmbH | 2019-06-28 |
| A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib (NCT03804515) | Spectrum Pharmaceuticals, Inc | 2019-06-25 |
| PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors (NCT04477057) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2019-06-21 |
| A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (NCT03829254) | NuCana plc | 2019-06-17 |
| Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia (NCT03973450) | Neuromed IRCCS | 2019-06-15 |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (NCT03839342) | University Health Network, Toronto | 2019-06-07 |
| A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies (NCT03471286) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-06-06 |
| A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers. (NCT03961100) | Genentech, Inc. | 2019-06-06 |
| Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer (NCT03994211) | BeiGene | 2019-05-29 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (NCT03960060) | Shanghai PerHum Therapeutics Co., Ltd. | 2019-05-16 |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer (NCT04001569) | Seoul National University Bundang Hospital | 2019-05-14 |
| Study of ORIC-101 in Combination With Anticancer Therapy (NCT03928314) | ORIC Pharmaceuticals | 2019-05-02 |
| Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors (NCT03940820) | Asclepius Technology Company Group (Suzhou) Co., Ltd. | 2019-05-01 |
| Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (NCT04122625) | Debiopharm International SA | 2019-04-26 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA (NCT04264767) | Nucleix Ltd. | 2019-04-17 |
| Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors (NCT03875287) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-04-17 |
| Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma (NCT03934814) | I-Mab Biopharma US Limited | 2019-04-16 |
| Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (NCT04276376) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-04-12 |
| TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT03884556) | Trishula Therapeutics, Inc. | 2019-04-10 |
| Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (NCT03647163) | Vyriad, Inc. | 2019-04-09 |
| Assessing Exercise Behavior and Preferences Among Patients and Oncologists (NCT04047589) | Indiana University | 2019-04-08 |
| OH2 Oncolytic Viral Therapy in Solid Tumors (NCT03866525) | Binhui Biopharmaceutical Co., Ltd. | 2019-04-02 |
| Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours (NCT03894540) | Ipsen | 2019-03-22 |
| Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) (NCT03834220) | Debiopharm International SA | 2019-03-22 |
| Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies (NCT03447470) | Redx Pharma Ltd | 2019-03-18 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer (NCT03861156) | InventisBio Co., Ltd | 2019-02-28 |
| Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours (NCT04810208) | Lidds AB | 2019-02-28 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| AO-176 in Multiple Solid Tumor Malignancies (NCT03834948) | Arch Oncology | 2019-02-04 |
| A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors (NCT03815630) | Allife Medical Science and Technology Co., Ltd. | 2019-02-01 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (NCT06065592) | Lebanese University | 2019-02-01 |
| A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors (NCT03815084) | Allife Medical Science and Technology Co., Ltd. | 2019-02-01 |
| A Study of LY3405105 in Participants With Advanced Cancer (NCT03770494) | Eli Lilly and Company | 2019-01-31 |
| Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015 (NCT03782467) | Alligator Bioscience AB | 2019-01-30 |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors (NCT03739827) | National Cancer Institute (NCI) | 2019-01-28 |
| Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors (NCT03810339) | Sun Yat-sen University | 2019-01-15 |
| Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors (NCT07357636) | Shantou University Medical College | 2019-01-10 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| M6620 (VX-970) in Selected Solid Tumors (NCT03718091) | Massachusetts General Hospital | 2019-01-08 |
| Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors (NCT03891706) | Guangzhou FineImmune Biotechnology Co., LTD. | 2019-01-08 |
| Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients (NCT03823989) | Lipomedix Pharmaceuticals Inc. | 2019-01-03 |
| Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms (NCT03601611) | Herlev Hospital | 2019-01-01 |
| Psychotherapy Intervention for Latinos With Adv Cancer (NCT04537936) | Memorial Sloan Kettering Cancer Center | 2019-01-01 |
| Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors (NCT03879057) | Peking University | 2018-12-21 |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (NCT03247309) | Immatics US, Inc. | 2018-12-19 |
| Clinical Study of ICP-192 in Solid Tumors Patients (NCT03758664) | Beijing InnoCare Pharma Tech Co., Ltd. | 2018-12-19 |
| A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors (NCT03844438) | Luye Pharma Group Ltd. | 2018-12-18 |
| Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (NCT03570619) | University of Michigan Rogel Cancer Center | 2018-12-14 |
| M6620 Plus Standard Treatment in Oesophageal and Other Cancer (NCT03641547) | University of Oxford | 2018-12-04 |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors (NCT03757936) | Shanghai Henlius Biotech | 2018-11-27 |
| A Study of LY3415244 in Participants With Advanced Solid Tumors (NCT03752177) | Eli Lilly and Company | 2018-11-22 |
| OH2 Injection in Solid Tumors (NCT04386967) | Binhui Biopharmaceutical Co., Ltd. | 2018-11-22 |
| SHR-1701 in Metastatic or Locally Advanced Solid Tumors (NCT03710265) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-20 |
| A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas (NCT03991559) | Chinese PLA General Hospital | 2018-11-01 |
| Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer (NCT03654716) | Dana-Farber Cancer Institute | 2018-11-01 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas (NCT03809767) | CStone Pharmaceuticals | 2018-10-29 |
| Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors (NCT03588039) | Athenex, Inc. | 2018-10-25 |
| RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (NCT03815682) | Repertoire Immune Medicines | 2018-10-24 |
| GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors (NCT03733587) | Genexine, Inc. | 2018-10-17 |
| Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. (NCT03544723) | MultiVir, Inc. | 2018-10-01 |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors (NCT03511222) | Washington University School of Medicine | 2018-09-11 |
| Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors (NCT03611595) | Peter Zage | 2018-08-28 |
| KN035 for dMMR/MSI-H Advanced Solid Tumors (NCT03667170) | 3D Medicines (Sichuan) Co., Ltd. | 2018-08-22 |
| A Trial of Ipatasertib in Combination With Atezolizumab (NCT03673787) | Institute of Cancer Research, United Kingdom | 2018-08-13 |
| Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma (NCT03600467) | St Vincent's Hospital, Sydney | 2018-08-13 |
| A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies (NCT03333031) | Herbert Lyerly | 2018-08-10 |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor (NCT03009292) | Eisai Co., Ltd. | 2018-08-06 |
| A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies (NCT03560882) | Joaquina Baranda | 2018-07-19 |
| Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies (NCT03987685) | Athenex, Inc. | 2018-07-19 |
| Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors (NCT03596593) | Peking University | 2018-07-11 |
| A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor (NCT04046016) | Seoul National University Hospital | 2018-07-03 |
| A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors (NCT03592264) | OBI Pharma, Inc | 2018-07-02 |
| A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation (NCT03781219) | Shanghai Kechow Pharma, Inc. | 2018-07-01 |
| A Study of Injection HB002.1T in Subjects With Solid Tumor (NCT03636750) | Huabo Biopharm Co., Ltd. | 2018-06-28 |
| Oral AMXT 1501 Dicaprate in Combination With DFMO (NCT03536728) | Aminex Therapeutics, Inc. | 2018-06-12 |
| Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor (NCT03406364) | Metagone Biotech Inc. | 2018-06-06 |
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study (NCT04260269) | Helsinki University Central Hospital | 2018-06-01 |
| Study of EOC317 in Chinese Patients With Advanced Solid Tumors (NCT03583125) | Taizhou EOC Pharma Co., Ltd. | 2018-05-29 |
| Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03489343) | Symphogen A/S | 2018-05-24 |
| Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor (NCT04366648) | JenKem Technology Co., Ltd. | 2018-05-04 |
| QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors (NCT03147976) | NantPharma, LLC | 2018-05-02 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (NCT03493945) | National Cancer Institute (NCI) | 2018-05-01 |
| A Study of PTS for Patients With Solid Tumors (NCT03448211) | PTS International Inc. | 2018-05-01 |
| Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors (NCT03552406) | ISU Abxis Co., Ltd. | 2018-04-27 |
| Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE). (NCT03447483) | Institut Claudius Regaud | 2018-04-20 |
| A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy (NCT03454620) | Green Cross Corporation | 2018-04-02 |
| PET Study With [89Zr]-Df-CriPec® Docetaxel (NCT03712423) | Amsterdam UMC, location VUmc | 2018-04-01 |
| Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors (NCT03644056) | ImmuneOncia Therapeutics Inc. | 2018-03-22 |
| Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (NCT03166176) | Samsung Medical Center | 2018-03-01 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (NCT03166904) | Samsung Medical Center | 2018-03-01 |
| Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850) | Tesaro, Inc. | 2018-02-20 |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (NCT03396445) | Merck Sharp & Dohme LLC | 2018-02-18 |
| Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors (NCT03468751) | Henlix, Inc | 2018-02-14 |
| Prospective Tissue Collection Research Protocol (NCT03517917) | AstraZeneca | 2018-02-08 |
| Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (NCT03707808) | Universitair Ziekenhuis Brussel | 2018-01-29 |
| Dabrafenib and/or Trametinib Rollover Study (NCT03340506) | Novartis Pharmaceuticals | 2018-01-26 |
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer (NCT02834052) | Asha Nayak | 2018-01-10 |